Abstract
The addition of atezolizumab (anti-PD-L1) to enzalutamide (androgen receptor antagonist) did not prolong survival in metastatic prostate cancer.1 Efficacy with immunotherapies in prostate cancer will require additional studies to elucidate and target mechanisms of resistance within the prostate tumor microenvironment.
Original language | English (US) |
---|---|
Article number | 100613 |
Journal | Cell Reports Medicine |
Volume | 3 |
Issue number | 4 |
DOIs |
|
State | Published - Apr 19 2022 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
- General Medicine